How Bristol-Myers and Pfizer are using real-world data to unseat warfarin

Eliquis, the pharmas' blood thinner, is now a blockbuster. Yet the companies see more growth ahead, tapping real-world data to convince doctors and payers.

By Ned Pagliarulo • Jan. 29, 2018

When real-world evidence becomes a real headache

After devoting considerable time and resources to find out how a product works in everyday life, drugmakers can be left with more questions than answers.

By Jacob Bell • Jan. 29, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Payers wade into real-world evidence, but tread lightly

Insurers and pharmacy benefit managers are wary about the quality of data underlying real-world evidence.

By David Lim • Jan. 29, 2018

ICER: High-priced Hemlibra could reduce hemophilia costs

Even though the drug's price is high, once-weekly Hemlibra could save costs for the U.S. healthcare system.

By Suzanne Elvidge • Jan. 29, 2018

US in 'desperate need' of biosimilars: Novartis' Narasimhan

Incoming CEO Vas Narasimhan expects significant uptake of biosimilars in the future, despite a sluggish start in the U.S. for the copycat biologics.  

By Ned Pagliarulo • Jan. 24, 2018

Novartis pulls Arzerra outside US markets amid rising CLL competition

In all markets except the U.S., the leukemia drug will only be available on a compassionate use basis. 

By Ned Pagliarulo • Jan. 24, 2018

NYC seeks $500M in suit aimed at opioid manufacturers

The Big Apple joins a chorus of cities, states and counties seeking retribution from prescription painkiller developers, including J&J and Purdue Pharma.

By Jacob Bell • Jan. 24, 2018

Novartis predicts growth pick-up on back of Cosentyx, Entresto

Incoming CEO Vas Narasimhan will soon step into the role, as the Swiss pharma looks to rebound from several years of declining operating profits.

By Ned Pagliarulo • Jan. 24, 2018

Drug price hikes drive health spending up

The Health Care Cost Institute found healthcare spending grew 4.6% last year.

By Jeff Byers • Jan. 23, 2018

J&J signals new tax laws won't change its M&A strategy

Despite a more favorable tax rate, J&J leadership said the company is still focused largely on early-stage acquisitions after a busy year of dealmaking.

By Jacob Bell • Jan. 23, 2018

FDA to speed public notification of product recalls

The move is part of the FDA's efforts to strengthen its enforcement of potentially unsafe food and medical products.

By Ned Pagliarulo • Jan. 19, 2018

Pharma, payers clash over CMS Part D drug rebate plan

The drug, PBM and insurance industries differ on a CMS proposal to require Part D sponsors to pass on a percentage of rebates to consumers.

By David Lim • Jan. 18, 2018

Shire's latest approval won't save it from Hemlibra

The EC thumbs up for Adynovi should bolster Shire's hemophilia business, yet Roche's new drug still threatens bottom lines. 

By Jacob Bell • Jan. 17, 2018

Novartis aims for US approval of Humira biosimilar

If OK'd by the FDA, the Swiss pharma's drug would be the third copycat version of the top-selling biologic product in the U.S.

By Suzanne Elvidge • Jan. 17, 2018

Price for Spark gene therapy too high, ICER says

Even considering indirect societal benefits, the group found Luxturna's $850,000 price tag would need to be cut in half to meet its cost-effectiveness thresholds.

By Ned Pagliarulo • Jan. 16, 2018

Novartis goes 2-0 against J&J in psoriasis

Fresh data support Cosentyx's superiority to Stelara in treating plaque psoriasis.

By Jacob Bell • Jan. 16, 2018

AstraZeneca's PARP inhibitor gains market edge with breast cancer approval

Lynparza, already one of AstraZeneca's fastest growing products, now holds a new indication over rival therapies from Clovis and Tesaro.

By Jacob Bell • Jan. 12, 2018

BioPharma Dive's 3 predictions for 2018 and beyond

What trends will shape the biopharma industry in 2018? BioPharma Dive's editors took a stab at predicting how the year may unfold for AI, oncology and neuroscience.

By Ned Pagliarulo • Jan. 12, 2018

Drug charity group bites back at HHS

Patient Services Inc. filed a lawsuit claiming recent guidance from the department violated the organization's First Amendment rights.

By Jacob Bell • Jan. 10, 2018

FDA slaps down Amneal bid to stop Forteo generics

The agency has rejected a citizen petition from the copycat drugmaker.

By Jacob Bell • Jan. 10, 2018

Price competition to hit oncology next: BioPharma Dive's 2018 predictions

Cancer drugs routinely command a premium price. A crowded pipeline of me-too rivals could change that. 

By Ned Pagliarulo • Jan. 10, 2018

JPM18: Allergan says no Restasis generic before second quarter

Allergan has fought hard against generic competitors to its blockbuster eye drug.

By Suzanne Elvidge • Jan. 10, 2018

Azar talks list prices, mandatory Medicare pilots

The HHS nominee identified high drug prices and shifting payment models to reward health outcomes as top priorities.

By David Lim • Jan. 9, 2018

FDA rejects Allergan's latest bid to block Restasis copies

Allergan could face generic competition to Restasis as soon as this year, bringing with it a potential blow to the company's bottom line.

By Ned Pagliarulo • Jan. 5, 2018

Drug approvals surged in 2017. What does that mean for pharma?

The FDA approved more novel medicines in 2017 than in any year since 1996.

By Ned Pagliarulo • Jan. 3, 2018